
Carlos A Torres-Cabala

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1159392/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Cutaneous Lymphoid Hyperplasia With T-Cell Clonality and Monotypic Plasma Cells Secondary to a Tick Bite: A Hidden Critter and the Power of Deeper Levels. American Journal of Dermatopathology, 2022, 44, 226-229.	0.6	2
2	Diverse landscape of dermatologic toxicities from smallâ€molecule inhibitor cancer therapy. Journal of Cutaneous Pathology, 2022, 49, 61-81.	1.3	5
3	Cutaneous balamuthiasis: AÂclinicopathological study. JAAD International, 2022, 6, 51-58.	2.2	6
4	The dilemma of primary γδ epidermotropic Tâ€cell lymphoma: Distinction from mycosis fungoides, signs of cytotoxicity, and need for more detailed analysis. Journal of Cutaneous Pathology, 2022, 49, 419-420.	1.3	2
5	Primary cutaneous Epsteinâ€Barr virusâ€positive Bâ€cell lymphoid proliferation with features of diffuse large Bâ€cell lymphoma and mucocutaneous ulcer: a diagnostic dilemma. International Journal of Dermatology, 2022, , .	1.0	0
6	Eosinophilic homogeneous intracytoplasmic inclusion bodies: Unique viral cytopathic changes associated with epidermodysplasia verruciformis and human papillomavirus type 49. Journal of Cutaneous Pathology, 2022, , .	1.3	1
7	Enhanced T-Cell Priming and Improved Anti-Tumor Immunity through Lymphatic Delivery of Checkpoint Blockade Immunotherapy. Cancers, 2022, 14, 1823.	3.7	4
8	Severe de novo pustular psoriasiform immuneâ€related adverse event associated with nivolumab treatment for metastatic esophageal adenocarcinoma. Journal of Cutaneous Pathology, 2022, 49, 472-481.	1.3	7
9	Treatment With Dupilumab for Refractory Cutaneous B-Cell Pseudolymphoma. JAMA Dermatology, 2022, 158, 697.	4.1	4
10	Genomic Correlates of Outcome in Tumor-Infiltrating Lymphocyte Therapy for Metastatic Melanoma. Clinical Cancer Research, 2022, 28, 1911-1924.	7.0	3
11	Cutaneous adnexal carcinosarcoma: Immunohistochemical and molecular evidence of epithelial mesenchymal transition. Journal of Cutaneous Pathology, 2021, 48, 526-534.	1.3	1
12	Langerhans cell sarcoma involving skin and showing epidermotropism: A comprehensive review. Journal of Cutaneous Pathology, 2021, 48, 547-557.	1.3	3
13	Prognostic significance of acral lentiginous histologic type in T1 melanoma. Modern Pathology, 2021, 34, 572-583.	5.5	8
14	TRPS1: a highly sensitive and specific marker for breast carcinoma, especially for triple-negative breast cancer. Modern Pathology, 2021, 34, 710-719.	5.5	90
15	Tertiary lymphoid structures with overlapping histopathologic features of cutaneous marginal zone lymphoma during neoadjuvant cemiplimab therapy are associated with antitumor response. Journal of Cutaneous Pathology, 2021, 48, 674-679.	1.3	4
16	Is immunohistochemical expression of GATA3 helpful in the differential diagnosis of transformed mycosis fungoides and primary cutaneous CD30-positive T cell lymphoproliferative disorders?. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 479, 377-383.	2.8	5
17	Diagnostic utility of <scp>PRAME</scp> in distinguishing proliferative nodules from melanoma in giant congenital melanocytic nevi. Journal of Cutaneous Pathology, 2021, 48, 1410-1415.	1.3	11
18	PARP and CDK4/6 Inhibitor Combination Therapy Induces Apoptosis and Suppresses Neuroendocrine Differentiation in Prostate Cancer, Molecular Cancer Therapeutics, 2021, 20, 1680-1691	4.1	22

#	Article	IF	CITATIONS
19	Gamma/Delta Phenotype in Primary Cutaneous T-cell Lymphomas and Lymphoid Proliferations. Surgical Pathology Clinics, 2021, 14, 177-194.	1.7	8
20	Telomerase Reverse Transcriptase Protein Expression Is More Frequent in Acral Lentiginous Melanoma Than in Other Types of Cutaneous Melanoma. Archives of Pathology and Laboratory Medicine, 2021, 145, 842-850.	2.5	0
21	Aggressive primary cutaneous anaplastic large cell lymphoma with massive bilateral upper limb involvement at relapse. JAAD Case Reports, 2021, 17, 34-37.	0.8	1
22	Localized cutaneous argyria: Review of a rare clinical mimicker of melanocytic lesions. Annals of Diagnostic Pathology, 2021, 54, 151776.	1.3	4
23	The utility of digital pathology in improving the diagnostic skills of pathology trainees in commonly encountered pigmented cutaneous lesions during the COVID-19 pandemic: A single academic institution experience. Annals of Diagnostic Pathology, 2021, 54, 151807.	1.3	7
24	Prognostic Significance of Subungual Anatomic Site in Acral Lentiginous Melanoma. Archives of Pathology and Laboratory Medicine, 2021, 145, 943-952.	2.5	8
25	Molecular characterization of biphenotypic epithelioid and plexiform melanoma with deep penetrating nevusâ€ike features. Pigment Cell and Melanoma Research, 2021, , .	3.3	3
26	Multimodality Imaging and Genetics of Primary Mucosal Melanomas and Response to Treatment. Radiographics, 2021, 41, 1954-1972.	3.3	2
27	Prognostic model for patient survival in primary anorectal mucosal melanoma: stage at presentation determines relevance of histopathologic features. Modern Pathology, 2020, 33, 496-513.	5.5	19
28	Cutaneous neoplasms composed of melanoma and carcinoma: A rare but important diagnostic pitfall and review of the literature. Journal of Cutaneous Pathology, 2020, 47, 36-46.	1.3	2
29	Diagnosis of T-cell lymphoid proliferations of the skin: putting all the pieces together. Modern Pathology, 2020, 33, 83-95.	5.5	6
30	Measurement of Tumor Thickness in Cutaneous Squamous Cell Carcinomas: Do the Different Methods Provide Better Prognostic Data?. American Journal of Dermatopathology, 2020, 42, 337-342.	0.6	9
31	Lymphomatoid Papulosis With a Unique T Follicular Helper–Like Phenotype. American Journal of Dermatopathology, 2020, 42, 776-779.	0.6	2
32	Pathology-based Biomarkers Useful for Clinical Decisions in Melanoma. Archives of Medical Research, 2020, 51, 827-838.	3.3	17
33	Apparent partial loss of CD123 expression in blastic plasmacytoid dendritic cell neoplasm after treatment with CD123â€ŧargeted therapy: A novel finding and possible diagnostic pitfall. Journal of Dermatology, 2020, 47, e354-e355.	1.2	1
34	Correlative study of epigenetic regulation of tumor microenvironment in spindle cell melanomas and cutaneous malignant peripheral nerve sheath tumors. Scientific Reports, 2020, 10, 12996.	3.3	6
35	Angioimmunoblastic T-cell lymphoma associated with immune checkpoint inhibitor treatment. JAAD Case Reports, 2020, 6, 1264-1267.	0.8	5
36	Hypertrophic lichenoid dermatitis immuneâ€related adverse event during combined immune checkpoint and exportin inhibitor therapy: A diagnostic pitfall for superficially invasive squamous cell carcinoma. Journal of Cutaneous Pathology, 2020, 47, 954-959.	1.3	8

#	Article	IF	CITATIONS
37	TERT amplification but not activation of canonical Wnt∫î²-catenin pathway is involved in acral lentiginous melanoma progression to metastasis. Modern Pathology, 2020, 33, 2067-2074.	5.5	6
38	BAP-1 Expression Status by Immunohistochemistry in Cellular Blue Nevus and Blue Nevus–like Melanoma. American Journal of Dermatopathology, 2020, 42, 313-321.	0.6	10
39	Lichen planus related to transforming growth factor beta inhibitor in a patient with metastatic chondrosarcoma: a case report. Journal of Cutaneous Pathology, 2020, 47, 490-493.	1.3	4
40	T-Cell Repertoire in Combination with T-Cell Density Predicts Clinical Outcomes in Patients with Merkel Cell Carcinoma. Journal of Investigative Dermatology, 2020, 140, 2146-2156.e4.	0.7	14
41	NCCN Guidelines Insights: Primary Cutaneous Lymphomas, Version 2.2020. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 522-536.	4.9	69
42	NCCN Guidelines Insights: T-Cell Lymphomas, Version 1.2021. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 1460-1467.	4.9	30
43	Lichenoid dermatitis from immune checkpoint inhibitor therapy: An immuneâ€related adverse event with mycosisâ€fungoidesâ€like morphologic and molecular features. Journal of Cutaneous Pathology, 2019, 46, 872-877.	1.3	4
44	Unusual cutaneous metastatic carcinoma. Annals of Diagnostic Pathology, 2019, 43, 151399.	1.3	10
45	Expression of PD-1 and PD-L1 in Extramammary Paget Disease: Implications for Immune-Targeted Therapy. Cancers, 2019, 11, 754.	3.7	21
46	PD1/PD-L1 Expression in Blastic Plasmacytoid Dendritic Cell Neoplasm. Cancers, 2019, 11, 695.	3.7	12
47	From mycosis fungoides to herpetic folliculitis: The significance of deeper H&E tissue sections in dermatopathology. Journal of Cutaneous Pathology, 2019, 46, 624-626.	1.3	1
48	Gene expression profiling of lichenoid dermatitis immuneâ€related adverse event from immune checkpoint inhibitors reveals increased CD14 ⁺ and CD16 ⁺ monocytes driving an innate immune response. Journal of Cutaneous Pathology, 2019, 46, 627-636.	1.3	27
49	Melanoma With Loss of BAP1 Expression in Patients With No Family History of BAP1-Associated Cancer Susceptibility Syndrome: A Case Series. American Journal of Dermatopathology, 2019, 41, 167-179.	0.6	14
50	Relationship between tumor-associated immune infiltrate and p16 staining over clinicopathological features in acral lentiginous melanoma. Clinical and Translational Oncology, 2019, 21, 1127-1134.	2.4	20
51	B7-H3 Expression in Merkel Cell Carcinoma–Associated Endothelial Cells Correlates with Locally Aggressive Primary Tumor Features and Increased Vascular Density. Clinical Cancer Research, 2019, 25, 3455-3467.	7.0	24
52	Immunohistochemical and Molecular Features of Melanomas Exhibiting Intratumor and Intertumor Histomorphologic Heterogeneity. Cancers, 2019, 11, 1714.	3.7	5
53	Level of tumor-infiltrating lymphocytes and density of infiltrating immune cells in different malignancies. Biomarkers in Medicine, 2019, 13, 1481-1491.	1.4	16
54	Aberrant DNA Methylation Predicts Melanoma-Specific Survival in Patients with Acral Melanoma. Cancers, 2019, 11, 2031.	3.7	23

#	Article	IF	CITATIONS
55	Correlation of Tumor Burden in Sentinel Lymph Nodes with Tumor Burden in Nonsentinel Lymph Nodes and Survival in Cutaneous Melanoma. Clinical Cancer Research, 2019, 25, 7585-7593.	7.0	17
56	Update on eighth edition American Joint Committee on Cancer classification for Merkel cell carcinoma and histopathological parameters that determine prognosis. Journal of Clinical Pathology, 2019, 72, 337-340.	2.0	23
57	Melanoma coexisting with solar elastosis: a potential pitfall in the differential diagnosis between nevus and melanoma. Human Pathology, 2019, 84, 270-274.	2.0	3
58	Postâ€radiation vascular lesions of the breast. Journal of Cutaneous Pathology, 2019, 46, 52-58.	1.3	17
59	Primary cutaneous CD4+ small―to mediumâ€sized pleomorphic Tâ€cell lymphoproliferative disorder in a pediatric patient successfully treated with lowâ€dose radiation. Pediatric Dermatology, 2019, 36, e23-e26.	0.9	4
60	BCAT1 and miR-2504: novel methylome signature distinguishes spindle/desmoplastic melanoma from superficial malignant peripheral nerve sheath tumor. Modern Pathology, 2019, 32, 338-345.	5.5	8
61	Update on eighth edition American Joint Committee on Cancer classification for cutaneous melanoma and overview of potential pitfalls in histological examination of staging parameters. Journal of Clinical Pathology, 2019, 72, 265-270.	2.0	21
62	Regressed melanocytic nevi secondary to pembrolizumab therapy: an emerging melanocytic dermatologic effect from immune checkpoint antibody blockade. International Journal of Dermatology, 2019, 58, 1045-1052.	1.0	11
63	Summary of expression of SPARC protein in cutaneous vascular neoplasms and mimickers. Annals of Diagnostic Pathology, 2018, 34, 151-154.	1.3	3
64	Metastatic melanoma with balloon/histiocytoid cytomorphology after treatment with immunotherapy: A histologic mimic and diagnostic pitfall. Journal of Cutaneous Pathology, 2018, 45, 545-549.	1.3	5
65	Dermatologic toxicity from novel therapy using antimicrobial peptide LLâ€37 in melanoma: A detailed examination of the clinicopathologic features. Journal of Cutaneous Pathology, 2018, 45, 539-544.	1.3	13
66	Dermatologic toxicity from immune checkpoint blockade therapy with an interstitial granulomatous pattern. Journal of Cutaneous Pathology, 2018, 45, 504-507.	1.3	25
67	Chronic granulomatous reaction in patients receiving vaccine immunotherapy for metastatic melanoma. JAAD Case Reports, 2018, 4, 87-90.	0.8	4
68	Granulomatous/sarcoid-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patients. , 2018, 6, 14.		118
69	Intratumoral and peritumoral lymphovascular invasion detected by D2-40 immunohistochemistry correlates with metastasis in primary cutaneous Merkel cell carcinoma. Human Pathology, 2018, 77, 98-107.	2.0	8
70	Differential expression of CCR4 in primary cutaneous gamma/delta (γâ,,Î) T cell lymphomas and mycosis fungoides: Significance for diagnosis and therapy. Journal of Dermatological Science, 2018, 89, 88-91.	1.9	13
71	Coccidioidomycosis Involving Lungs and Skin: A Mimicker of Metastatic Disease. American Journal of Dermatopathology, 2018, 40, e41-e43.	0.6	6
72	Primary cutaneous plasmablastic lymphoma in an immunocompetent patient: is it associated with an indolent course?. Leukemia and Lymphoma, 2018, 59, 1753-1755.	1.3	5

#	Article	IF	CITATIONS
73	Angiotropism in recurrent cutaneous squamous cell carcinoma: Implications for regional tumor recurrence and extravascular migratory spread. Journal of Cutaneous Pathology, 2018, 46, 152-158.	1.3	5
74	A phase II trial of recombinant MAGE-A3 protein with immunostimulant AS15 in combination with high-dose Interleukin-2 (HDIL2) induction therapy in metastatic melanoma. BMC Cancer, 2018, 18, 1274.	2.6	31
75	Dermal xanthomatous infiltrates after brentuximab vedotin therapy in mycosis fungoides with largeâ€cell transformation: A novel histologic finding. Journal of Cutaneous Pathology, 2018, 45, 711-715.	1.3	2
76	Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome. Clinical Cancer Research, 2018, 24, 4416-4428.	7.0	89
77	Suprabasal acantholytic dermatologic toxicities associated checkpoint inhibitor therapy: A spectrum of immune reactions from paraneoplastic pemphigusâ€like to Groverâ€like lesions. Journal of Cutaneous Pathology, 2018, 45, 764-773.	1.3	38
78	Calcinosis cutis dermatologic toxicity associated with fibroblast growth factor receptor inhibitor for the treatment of Wilms tumor. Journal of Cutaneous Pathology, 2018, 45, 786-790.	1.3	18
79	Concomitant Cutaneous Langerhans Cell Hystiocytosis and Leukemia Cutis. American Journal of Dermatopathology, 2017, 39, 388-392.	0.6	11
80	Immunophenotypic Shifts in Primary Cutaneous Î ³ δ T-Cell Lymphoma Suggest Antigenic Modulation. American Journal of Surgical Pathology, 2017, 41, 431-445.	3.7	12
81	Lichenoid Dermatologic Toxicity From Immune Checkpoint Blockade Therapy: A Detailed Examination of the Clinicopathologic Features. American Journal of Dermatopathology, 2017, 39, 121-129.	0.6	96
82	High cytotoxic T-lymphocyte-associated antigen 4 and phospho-Akt expression in tumor samples predicts poor clinical outcomes in ipilimumab-treated melanoma patients. Melanoma Research, 2017, 27, 24-31.	1.2	15
83	Isolated Ectopic Cutaneous Atypical Meningioma of the Scalp: Another Mimicker of Primary Adnexal Tumor. American Journal of Dermatopathology, 2017, 39, 545-547.	0.6	5
84	Metastatic Melanoma With Papillary Features: A Mimic and Possible Diagnostic Pitfall. American Journal of Dermatopathology, 2017, 39, 468-470.	0.6	3
85	Primary Cutaneous T-Cell Lymphomas Showing Gamma-Delta (Î ³ Î) Phenotype and Predominantly Epidermotropic Pattern are Clinicopathologically Distinct From Classic Primary Cutaneous Î ³ δT-Cell Lymphomas. American Journal of Surgical Pathology, 2017, 41, 204-215.	3.7	57
86	EBV-negative Aggressive NK-cell Leukemia/Lymphoma. American Journal of Surgical Pathology, 2017, 41, 67-74.	3.7	59
87	Tumor infiltrating lymphocytes in acral lentiginous melanoma: a study of a large cohort of cases from Latin America. Clinical and Translational Oncology, 2017, 19, 1478-1488.	2.4	46
88	Intraepithelial Melanoma in the Stomach After Treatment With Immune Checkpoint Blockade Therapy. American Journal of Dermatopathology, 2017, 39, e116-e118.	0.6	5
89	Tumor Thickness and Mitotic Rate Robustly Predict Melanoma-Specific Survival in Patients with Primary Vulvar Melanoma: A Retrospective Review of 100 Cases. Clinical Cancer Research, 2017, 23, 2093-2104.	7.0	48
90	Indeterminate dendritic cell neoplasm of the skin: A 2 ase report and review of the literature. Journal of Cutaneous Pathology, 2017, 44, 958-963.	1.3	23

#	Article	IF	CITATIONS
91	Erythema nodosumâ€like panniculitis mimicking disease recurrence: A novel toxicity from immune checkpoint blockade therapy—Report of 2 patients. Journal of Cutaneous Pathology, 2017, 44, 1080-1086.	1.3	48
92	Chronic myelomonocytic leukemia masquerading as cutaneous indeterminate dendritic cell tumor: Expanding the spectrum of skin lesions in chronic myelomonocytic leukemia. Journal of Cutaneous Pathology, 2017, 44, 1075-1079.	1.3	27
93	Detection of Merkel Cell Polyoma Virus and Beta Human Papillomavirus in Multiple Eccrine Poromas in a Patient With Acute Leukemia Treated With Stem Cell Transplant. American Journal of Dermatopathology, 2017, 39, 489-491.	0.6	8
94	Aberrant expression of <scp>FLI</scp> â€l in melanoma. Journal of Cutaneous Pathology, 2017, 44, 790-793.	1.3	5
95	Diverse types of dermatologic toxicities from immune checkpoint blockade therapy. Journal of Cutaneous Pathology, 2017, 44, 158-176.	1.3	186
96	Clinical significance of BRAF V600E mutational status in capsular nevi of sentinel lymph nodes in patients with primary cutaneous melanoma. Human Pathology, 2017, 59, 48-54.	2.0	8
97	A case of indeterminate dendritic cell tumor presenting with leonine facies. Journal of Cutaneous Pathology, 2016, 43, 158-163.	1.3	12
98	Giemsa is the optimal counterstain for immunohistochemical detection of <scp>BRAF V600E</scp> mutation status in pigmented melanomas. Journal of Cutaneous Pathology, 2016, 43, 722-724.	1.3	9
99	Autoimmune dermatologic toxicities from immune checkpoint blockade with antiâ€ <scp>PD</scp> â€1 antibody therapy: a report on bullous skin eruptions. Journal of Cutaneous Pathology, 2016, 43, 688-696.	1.3	126
100	Primary Cutaneous Gamma-Delta (γ/Î) T-cell Lymphoma: An Unusual Case With Very Subtle Histopathological Findings. American Journal of Dermatopathology, 2016, 38, e147-e149.	0.6	7
101	Density, Distribution, and Composition of Immune Infiltrates Correlate with Survival in Merkel Cell Carcinoma. Clinical Cancer Research, 2016, 22, 5553-5563.	7.0	96
102	Clinicopathological and molecular study of primary cutaneous CD4+ small/mediumâ€sized pleomorphic Tâ€cell lymphoma. Journal of Cutaneous Pathology, 2016, 43, 1121-1130.	1.3	34
103	Cutaneous histoplasmosis with prominent parasitization of epidermal keratinocytes: report of a case. Journal of Cutaneous Pathology, 2016, 43, 1155-1160.	1.3	7
104	Loss of <scp>CD30</scp> expression after treatment with brentuximab vedotin in a patient with anaplastic large cell lymphoma: a novel finding. Journal of Cutaneous Pathology, 2016, 43, 1161-1166.	1.3	40
105	Cutaneous metastasis from anaplastic thyroid carcinoma exhibiting exclusively a spindle cell morphology. A case report and review of literature. Journal of Cutaneous Pathology, 2016, 43, 252-257.	1.3	8
106	BRAF inhibitor therapy–associated melanocytic lesions lack the BRAF V600E mutation and show increased levels of cyclin D1 expression. Human Pathology, 2016, 50, 79-89.	2.0	18
107	Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy. Cancer Discovery, 2016, 6, 202-216.	9.4	1,158
108	Proliferation indices correlate with diagnosis and metastasis in diagnostically challenging melanocytic tumors. Human Pathology, 2016, 53, 73-81.	2.0	11

#	Article	IF	CITATIONS
109	Molecular characteristics and potential therapeutic targets in Merkel cell carcinoma. Journal of Clinical Pathology, 2016, 69, 382-390.	2.0	19
110	Dermatologic Toxicities to Melanoma Targeted Therapies. , 2016, , 267-277.		1
111	Biomarker Analysis of Gene-Mutated Protein Products by Immunohistochemistry in Melanoma. , 2016, , 181-191.		0
112	Immunohistology and Molecular Studies of Cutaneous T-Cell Lymphomas and Mimics. , 2016, , 229-259.		0
113	Immunohistology of Melanocytic Lesions. , 2016, , 311-334.		0
114	Role of Radiotherapy in Aggressive Digital Papillary Adenocarcinoma. Annals of Clinical and Laboratory Science, 2016, 46, 222-4.	0.2	5
115	Panniculitis With Necrotizing Granulomata in a Patient on BRAF Inhibitor (Dabrafenib) Therapy for Metastatic Melanoma. American Journal of Dermatopathology, 2015, 37, e96-e99.	0.6	18
116	Use of clinical nextâ€generation sequencing to identify melanomas harboring <i><scp>SMARCB1</scp></i> mutations. Journal of Cutaneous Pathology, 2015, 42, 308-317.	1.3	11
117	Metastatic Atypical Fibroxanthoma. American Journal of Dermatopathology, 2015, 37, 455-461.	0.6	40
118	Emerging clinical applications of selected biomarkers in melanoma. Clinical, Cosmetic and Investigational Dermatology, 2015, 8, 35.	1.8	18
119	An unusual case of cytotoxic peripheral T-cell lymphoma. JAAD Case Reports, 2015, 1, 257-260.	0.8	4
120	HTLV-1-associated infective dermatitis demonstrates low frequency of FOXP3-positive T-regulatory lymphocytes. Journal of Dermatological Science, 2015, 77, 150-155.	1.9	11
121	Utility of BRAF V600E Immunohistochemistry Expression Pattern as a Surrogate of BRAF Mutation Status in 154 Patients with Advanced Melanoma. Human Pathology, 2015, 46, 1101-1110.	2.0	43
122	Beyond BRAF V600 : Clinical Mutation Panel Testing by Next-Generation Sequencing in Advanced Melanoma. Journal of Investigative Dermatology, 2015, 135, 508-515.	0.7	138
123	Hematolymphoid Proliferations of the Skin. Molecular Pathology Library, 2015, , 3-36.	0.1	2
124	Infectious Diseases of the Skin. Molecular Pathology Library, 2015, , 81-102.	0.1	0
125	Somatic rearrangement of the TP63 gene preceding development of mycosis fungoides with aggressive clinical course. Blood Cancer Journal, 2014, 4, e253-e253.	6.2	16
126	Primary Cutaneous CD8+ T-cell Lymphoma Masquerading as Acral Vascular Syndrome. Acta Dermato-Venereologica, 2014, 94, 317-319.	1.3	3

#	Article	IF	CITATIONS
127	Immunophenotypic shift of <scp>CD4</scp> and <scp>CD8</scp> antigen expression in primary cutaneous Tâ€cell lymphomas: a clinicopathologic study of three cases. Journal of Cutaneous Pathology, 2014, 41, 51-57.	1.3	19
128	Pigmented extramammary Paget disease of the thigh mimicking a melanocytic tumor: report of a case and review of the literature. Journal of Cutaneous Pathology, 2014, 41, 529-535.	1.3	19
129	The differential diagnosis of CD8â€positive ("type Dâ€) lymphomatoid papulosis. Journal of Cutaneous Pathology, 2014, 41, 88-100.	1.3	48
130	Sweet syndrome following vemurafenib therapy for recurrent cholangiocarcinoma. Journal of Cutaneous Pathology, 2014, 41, 326-328.	1.3	28
131	Histological Features Associated With Vemurafenib-Induced Skin Toxicities. American Journal of Dermatopathology, 2014, 36, 557-561.	0.6	17
132	p40 Is More Specific Than p63 for the Distinction of Atypical Fibroxanthoma From Other Cutaneous Spindle Cell Malignancies. American Journal of Surgical Pathology, 2014, 38, 1102-1110.	3.7	31
133	Extranodal Marginal Zone Lymphoma From Ocular Adnexae With Subcutaneous Involvement. American Journal of Dermatopathology, 2014, 36, e189-e193.	0.6	3
134	Diagnostic Utility and Comparative Immunohistochemical Analysis of MITF-1 and SOX10 to Distinguish Melanoma In Situ and Actinic Keratosis. American Journal of Dermatopathology, 2014, 36, 124-130.	0.6	43
135	Detection of mitotic figures and <scp>G2</scp> + tumor nuclei with histone markers correlates with worse overall survival in patients with Merkel cell carcinoma. Journal of Cutaneous Pathology, 2014, 41, 846-852.	1.3	16
136	Dermatologic toxicities to targeted cancer therapy: shared clinical and histologic adverse skin reactions. International Journal of Dermatology, 2014, 53, 376-384.	1.0	62
137	Melanoma arising in association with blue nevus: a clinical and pathologic study of 24 cases and comprehensive review of the literature. Modern Pathology, 2014, 27, 1468-1478.	5.5	54
138	GNAQmutation in a patient with metastatic mucosal melanoma. BMC Cancer, 2014, 14, 516.	2.6	18
139	Novel Intra-Adrenal Secondary Lymphoid Follicle Formation. Endocrine Pathology, 2013, 24, 248-249.	9.0	1
140	Immunodetection of phosphohistone H3 as a surrogate of mitotic figure count and clinical outcome in cutaneous melanoma. Modern Pathology, 2013, 26, 1153-1160.	5.5	67
141	Ambiguous Melanocytic Tumors in a Tertiary Referral Center. American Journal of Surgical Pathology, 2013, 37, 1783-1796.	3.7	31
142	Impact of the 2009 (7th Edition) AJCC Melanoma Staging System in the Classification of Thin Cutaneous Melanomas. BioMed Research International, 2013, 2013, 1-7.	1.9	15
143	Changes in Tumor Morphology and Cyclin-Dependent Kinase Inhibitor Expression in Metastatic Melanoma Treated With Selective Second-Generation BRAF Inhibitor. American Journal of Dermatopathology, 2013, 35, 125-128.	0.6	5
144	H3K79me3T80ph is a Novel Histone Dual Modification and a Mitotic Indicator in Melanoma. Journal of Skin Cancer, 2012, 2012, 1-9.	1.2	12

CARLOS A TORRES-CABALA

#	Article	IF	CITATIONS
145	Anaplastic Oligodendroglioma Involving the Subcutaneous Tissue of the Scalp. American Journal of Dermatopathology, 2012, 34, 214-219.	0.6	7
146	Syringocystadenocarcinoma Papilliferum With Transition to Areas of Squamous Differentiation. American Journal of Dermatopathology, 2012, 34, 428-433.	0.6	19
147	Molecular Platforms Utilized to Detect BRAF V600E Mutation in Melanoma. Seminars in Cutaneous Medicine and Surgery, 2012, 31, 267-273.	1.6	48
148	The utility of <scp>ATF3</scp> in distinguishing cutaneous squamous cell carcinoma among other cutaneous epithelial neoplasms. Journal of Cutaneous Pathology, 2012, 39, 762-768.	1.3	6
149	Primary Cutaneous Small- to Medium-Sized CD4+ Pleomorphic T-Cell Lymphoma. American Journal of Clinical Dermatology, 2011, 12, 1.	6.7	23
150	Positive Sentinel Node in Sebaceous Carcinoma of the Eyelid. Ophthalmic Plastic and Reconstructive Surgery, 2011, 27, e4-e6.	0.8	33
151	Resistant mechanisms to BRAF inhibitor PLX4032 in melanoma. Expert Review of Dermatology, 2011, 6, 355-357.	0.3	2
152	Cutaneous epithelioid angiomatous nodule of the chest wall with expression of estrogen receptor: a mimic of carcinoma and a potential diagnostic pitfall. Journal of Cutaneous Pathology, 2011, 38, no-no.	1.3	7
153	Severe architectural disorder is a potential pitfall in the diagnosis of small melanocytic lesions. Journal of Cutaneous Pathology, 2010, 37, 860-865.	1.3	10
154	Cutaneous Metastases of Malignant Melanoma: A Clinicopathologic Study of 192 Cases With Emphasis on the Morphologic Spectrum. American Journal of Dermatopathology, 2010, 32, 129-136.	0.6	97
155	Detection of Human Papillomavirus in Multiple Eccrine Poromas in a Patient With Chronic Graft-vs-Host Disease and Immunosuppression. Archives of Dermatology, 2010, 147, 120.	1.4	16
156	Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acral-lentiginous/mucosal type. Modern Pathology, 2009, 22, 1446-1456.	5.5	196
157	HERâ€2/neu expression in extramammary Paget disease: a clinicopathologic and immunohistochemistry study of 47 cases with and without underlying malignancy. Journal of Cutaneous Pathology, 2009, 36, 729-733.	1.3	77
158	Immunohistochemical Expression of S100A6 in Cellular Neurothekeoma: Clinicopathologic and Immunohistochemical Analysis of 31 Cases. American Journal of Dermatopathology, 2009, 31, 419-422.	0.6	62
159	Lymphomatoid Granulomatosis With Involvement of the Hard Palate: A Case Report. Journal of Oral and Maxillofacial Surgery, 2008, 66, 2161-2163.	1.2	17
160	The Morphologic Spectrum of Kidney Tumors in Hereditary Leiomyomatosis and Renal Cell Carcinoma (HLRCC) Syndrome. American Journal of Surgical Pathology, 2007, 31, 1578-1585.	3.7	361
161	Hereditary Leiomyomatosis and Renal Cell Cancer: A Syndrome Associated With an Aggressive Form of Inherited Renal Cancer. Journal of Urology, 2007, 177, 2074-2080.	0.4	235
162	Expression of Hypoxia Inducible Factor-1α and 2α in Genetically Distinct Early Renal Cortical Tumors. Journal of Urology, 2006, 175, 1908-1914.	0.4	28

CARLOS A TORRES-CABALA

#	Article	IF	CITATIONS
163	Proteomic Identification of New Biomarkers and Application in Thyroid Cytology. Acta Cytologica, 2006, 50, 518-528.	1.3	50
164	Ganglion cyst in a 52-year-old man with metastatic melanoma. Diagnostic Cytopathology, 2006, 34, 485-485.	1.0	1
165	Fine-needle aspiration of a Xp11.2 translocation/TFE3 fusion renal cell carcinoma metastatic to the lung: Report of a case and review of the literature. Diagnostic Cytopathology, 2006, 34, 751-756.	1.0	42
166	HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: Novel role of fumarate in regulation of HIF stability. Cancer Cell, 2005, 8, 143-153.	16.8	843
167	Role of Chromogenic in Situ Hybridization (CISHâ,,¢) in the Evaluation of HER2 Status in Breast Carcinoma: Comparison with Immunohistochemistry and Fish. International Journal of Surgical Pathology, 2005, 13, 343-351.	0.8	35
168	High Frequency of Somatic Frameshift BHD Gene Mutations in Birt-Hogg-Dubé–Associated Renal Tumors. Journal of the National Cancer Institute, 2005, 97, 931-935.	6.3	213
169	EVALUATION AND MANAGEMENT OF RENAL TUMORS IN THE BIRT-HOGG-DUBÉ SYNDROME. Journal of Urology, 2005, 173, 1482-1486.	0.4	260
170	The In vitro and In vivo Effects of Re-Expressing Methylated von Hippel-Lindau Tumor Suppressor Gene in Clear Cell Renal Carcinoma with 5-Aza-2′-deoxycytidine. Clinical Cancer Research, 2004, 10, 7011-7021.	7.0	49
171	Expression of Birt–Hogg–Dubé gene mRNA in normal and neoplastic human tissues. Modern Pathology, 2004, 17, 998-1011.	5.5	124
172	Differential Expression of S100C in Thyroid Lesions. International Journal of Surgical Pathology, 2004, 12, 107-115.	0.8	20
173	EARLY ONSET HEREDITARY PAPILLARY RENAL CARCINOMA: GERMLINE MISSENSE MUTATIONS IN THE TYROSINE KINASE DOMAIN OF THE MET PROTO-ONCOGENE. Journal of Urology, 2004, 172, 1256-1261.	0.4	115
174	Predicting survival in patients with metastatic kidney cancer by gene-expression profiling in the primary tumor. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 6958-6963.	7.1	165